Executive Director, Global Health Economics and Outcomes Research

BioMarin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health. Since our founding in 1997, we have applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities. Using our unparalleled expertise in genetics and molecular biology, we develop medicines for patients with significant unmet medical need.

The Executive Director, Global Health Economics and Outcomes Research (HEOR), will lead the global HEOR function, with a portfolio comprising both mature, marketed products and late-stage assets in pre-launch. This role is accountable for defining and executing integrated global evidence and value strategies across the full product lifecycle, from early development through post-launch optimization. The Executive Director HEOR reports to the SVP Global Head of Pricing, Access, Value and Evidence (PAVE) and is a member of PAVE leadership team.

The position and his/her team will act as a strategic partner to Global Market Access, Medical Affairs, Clinical Development, Commercial, and Patient Advocacy teams, ensuring that payer-relevant, patient-centered evidence, and HTA submissions support successful launches, sustained reimbursement, and long-term value realization worldwide.

RESPONSIBILITIES

• Global HEOR Strategy & Leadership: Define and own the global HEOR strategy across marketed products and pipeline assets, aligned with corporate and portfolio priorities. Provide strategic leadership and direction to a global HEOR team, fostering scientific excellence and operational rigor. Manage external vendors, academic partnerships, and research collaborations to deliver high-quality evidence efficiently.
• Pre-Launch & Early Asset Strategy: Lead early value and evidence planning for late-stage and pre-launch assets, including development of global value stories and integrated evidence plans. Partner with Clinical Development to ensure trial designs, endpoints, and comparators address future HTA and payer requirements, particularly in rare diseases. Inform Target Product Profiles (TPPs) and access-relevant decision‑making during development.
• Launch & Market Access Enablement: Support global and regional Market Access teams with HEOR inputs for launch planning, pricing strategy, and reimbursement submissions. Oversee development of global value dossiers, cost‑effectiveness models, budget impact analyses, and AMCP/HTA submissions. Anticipate and address access challenges in key markets, including evidence uncertainty common in rare and ultra‑rare indications.
• Post‑Launch & Lifecycle Management: Drive post‑launch evidence generation, including real‑world evidence (RWE), registries, and long‑term outcomes studies, to support label expansions, re‑assessments, and sustained reimbursement. Optimize value demonstration for mature brands through updated economic models, new endpoints, and evolving payer needs. Monitor changes in global HTA and payer landscapes and proactively adapt evidence strategies.
• Patient‑Centric & Cross‑Functional Collaboration: Ensure integration of patient‑reported outcomes (PROs), quality‑of‑life, caregiver burden, and disease burden data into global evidence strategies. Collaborate closely with Medical Affairs on publications, scientific exchange, and congress strategy. Partner with Patient Advocacy and external stakeholders to embed the patient voice in value narratives.
• Scientific Leadership & External Engagement: Oversee HEOR publications, abstracts, and presentations at major international congresses (e.g., ISPOR, HTAi, DIA). Represent the company in external scientific, policy, and payer‑related forums. Ensure all HEOR activities comply with global regulatory, ethical, and scientific standards.

SCOPE Global position.EDUCATION PhD, DrPH, PharmD, MD, or equivalent advanced degree in Health Economics, Outcomes Research, Public Health, Epidemiology, Health Policy, or related discipline. Fluent in English.EXPERIENCE Minimum 15+ years of commercial experience in the pharmaceutical industry, with minimum of 10+ years of HEOR experience in pharmaceutical or biotechnology companies, with significant exposure to rare diseases and global roles. Demonstrated success supporting global launches and pre‑launch assets, as well as lifecycle management of marketed products. Proven experience engaging with HTA bodies and payer stakeholders across major markets (US, EU, UK, Japan). Experience leading multicultural teams. With experience of specialty care products in highly competitive markets. Experience in rare diseases market would be a plus. Proven track record of marketing across multiple stages of a product's life cycle. Successful Global launch experience in specialty and/or rare disease, preferably in the specific therapeutic area. Strong leadership skills and business acumen. Demonstrated agility, accountability, sense of urgency and team spirit. Capability to embark and enroll cross functional stakeholders at all levels of the organizations. Ability to build strong relationships across cultures, backgrounds and functions. Can manage complex situations and demonstrated ability to make decisions. Strong planning and project management skills – can and has successfully driven projects involving several departments and functions. Ability to convey complex information succinctly & simply (including verbal, written and in presentations). Resilience and openness to change. Complies with Company guidelines and country/industry standards on ethics and compliance and acts as a role model for ethical behavior.